

**DRUG NAME: Pamidronate****SYNONYM(S):** Pamidronate disodium, pamidronic acid, APD, aminohydroxypropylidene bisphosphonate**COMMON TRADE NAME(S):** AREDIA®**CLASSIFICATION:** Bone metabolism regulator*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Pamidronate is a second-generation bisphosphonate, which inhibits bone resorption.<sup>1</sup> Bisphosphonates are analogues of endogenous pyrophosphate and characterized by a P-C-P bond, which is resistant to enzymatic hydrolysis.<sup>2</sup> The mechanism of action of bisphosphonates has not been fully elucidated. Available data suggests that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions of matrix-bound bisphosphonates may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis and interference with osteoblast-mediated osteoclast activation.<sup>3</sup> Pamidronate does not interfere with bone mineralization at therapeutic doses.<sup>1</sup> On a molar basis, pamidronate is 10 times more potent than clodronate.<sup>2</sup> In tumour-induced hypercalcemia, bone resorption is increased in the presence of neoplastic tissue. Pamidronate inhibits abnormal bone resorption and reduces the flow of calcium from the resorbing bone into the blood, thus, decreasing total and ionized serum calcium. In the treatment of osteolytic bone metastases in breast cancer and multiple myeloma, pamidronate helps reducing morbidity of bone metastases by inhibiting accelerated bone resorption induced by the tumour.<sup>4</sup>

**PHARMACOKINETICS:**

Interpatient variability	no information found	
Oral Absorption	<1% absorbed <sup>5</sup>	
Distribution	45-53% is adsorbed to bone in the areas of high turnover after an intravenous dose of 60 mg infused over 24 hours. <sup>4</sup> Body retention of pamidronate correlates with the number of bone metastases in patients with cancer. <sup>3</sup>	
	cross blood brain barrier?	no information found
	volume of distribution	no information found
	plasma protein binding	54% <sup>4</sup>
Metabolism	does not appear to be metabolized	
	active metabolite(s)	none
	inactive metabolite(s)	none
Excretion	renal excretion; there is a tendency for renal clearance to correlate with creatinine clearance.	
	urine	20-55% as unchanged drug within 72 hours
	terminal half life	27 hours
	clearance	180 mL/min

Adapted from reference<sup>6</sup> unless specified otherwise

**USES:****Primary uses:**\*Tumour-induced hypercalcemia<sup>7-9</sup>\*Osteolytic bone metastases<sup>11-15</sup>

\*Health Canada approved indication

**Other uses:**Bone loss due to androgen suppression in prostate cancer<sup>10</sup>**SPECIAL PRECAUTIONS:****Contraindications:**

- history of hypersensitivity reaction to pamidronate or other bisphosphonates<sup>4,6</sup>

**Caution:**

- **Hydration:** In the treatment of acute tumour-induced hypercalcemia, patients must be adequately hydrated with intravenous NS (0.9% NaCl) before and during pamidronate therapy to expand intracellular volume and to increase renal calcium clearance.<sup>7,9</sup> The optimum infusion rate of NS should be determined by the severity of hypercalcemia, the degree of dehydration and the ability of the patient to tolerate fluid. Infusion rate of 200-300 mL/h has been commonly used. However, these infusion rates may require adjustment if signs and symptoms of fluid overload occur.<sup>9</sup>

**Carcinogenicity:** Studies on rats and mice did not find pamidronate to have carcinogenic potential.<sup>6</sup>

**Mutagenicity:** Pamidronate was not mutagenic in Ames test, mammalian *in vitro* mutation test or mammalian *in vivo* chromosome test.<sup>6</sup>

**Fertility:** No information found.<sup>4</sup>

**Pregnancy:** FDA Pregnancy Category C.<sup>4</sup> Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

**Breastfeeding** is not recommended due to the potential secretion into breast milk.<sup>6</sup>

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important (reference expert reviewer). When placebo-controlled trials are available, adverse events are included if the incidence is >5% higher in the treatment group except where indicated.

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
blood/bone marrow/ febrile neutropenia	anemia* (35%)
	granulocytopenia* (17%)
	lymphocytopenia (1-10%)
	thrombocytopenia* (11%)
constitutional symptoms	asthenia* (16%)
	fatigue* (30%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
	fever (36%)
dermatology/skin	<i>extravasation hazard</i> : none
	injection site reaction (2%)
gastrointestinal	<i>emetogenic potential</i> : nonemetogenic
	anorexia* (21%)
	constipation* (28%)
	diarrhea* (24%)
	dyspepsia* (14%)
	nausea* (48%)
	vomiting* (31%)
infection	upper respiratory infection* (20%)
	urinary tract infection* (15%)
metabolic/laboratory	hypocalcemia (3%)
	hypomagnesemia (1-10%)
	hypophosphatemia (>10%)
musculoskeletal	osteonecrosis of the jaw (rare) <sup>16-18</sup>
neurology	insomnia* (18%)
ocular/visual	conjunctivitis (rare) <sup>15</sup>
	uveitis (rare) <sup>15</sup>
pain	abdominal pain* (17%)
	headache* (24%)
	myalgia (23%)
	skeletal pain (59%)
pulmonary	cough* (21%)
	dyspnea* (23%)
syndromes	flu-like symptoms (>10%)

Adapted from reference<sup>6</sup> unless otherwise specified.

\*The incidences of these side effects are comparable to those of placebo group.

**Fever** is a transient febrile reaction with > 1°C elevation in body temperature and may last up to 48 hours.<sup>6</sup> The fever usually occurs within 5 days of the first infusion of pamidronate and it may be accompanied by myalgia, nausea and headache.<sup>3</sup> It is usually self-limiting and does not require treatment.<sup>6</sup> If treatment is needed, acetaminophen may be used. Reducing the infusion rate is usually not helpful.<sup>3</sup>

Symptomatic **hypocalcemia** is rare<sup>3</sup> and the symptoms include abdominal cramps, confusion, muscle spasms, lethargy and irritability.<sup>4,19</sup> Patients who have undergone thyroid surgery may be more prone to develop hypocalcemia after pamidronate therapy and should be monitored closely.<sup>6,19</sup> Symptomatic hypocalcemia can be treated with oral or intravenous calcium supplement.<sup>6,19</sup>

**Osteonecrosis of the jaw (ONJ)** is a rare, but serious event that has been associated with antiresorptive agents such as bisphosphonate therapy. Osteonecrosis of other anatomical sites (e.g., femur, hip, auditory canal,

metatarsal bones, etc.) have also been rarely reported.<sup>20</sup> ONJ is more commonly observed with increasing bisphosphonate potency, dose intensity, and duration of treatment, particularly when treatment exceeds four years.<sup>21-23</sup> The risk of ONJ is higher with intravenous than with oral bisphosphonate treatment.<sup>24,25</sup> Multiple risk factors may play a role, including invasive dental procedures and pre-existing dental disease,<sup>23,26</sup> concomitant therapy with angiogenesis inhibitors, corticosteroids, and radiation to the head and neck<sup>22-25</sup>, as well as certain comorbid medical conditions (e.g., anemia<sup>24,26</sup>, cancer<sup>22,25</sup>, coagulopathies<sup>24</sup>, and diabetes<sup>22,27</sup>). For further details and management of ONJ, refer to *Bisphosphonates and Osteonecrosis of the Jaw* in [Oral & Dental Care: Osteonecrosis of the Jaw](#).

#### INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
calcium- or vitamin D-containing preparations <sup>4</sup>	may antagonize the effect of pamidronate in the treatment of hypercalcemia	additive	avoid concurrent therapy

#### SUPPLY AND STORAGE:

**Injection:** 30 mg, 60 mg and 90 mg vials; (as anhydrous pamidronate disodium); Preservative-free.<sup>6</sup> Store at room temperature.<sup>4</sup>

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.**

#### SOLUTION PREPARATION AND COMPATIBILITY:

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.**

**Additional information:** It is recommended that pamidronate not be mixed with calcium-containing infusion solutions, such as Ringer's solution.<sup>6</sup>

**Compatibility:** consult detailed reference

#### PARENTERAL ADMINISTRATION:

	BC Cancer administration standard noted in <b><i>bold, italics</i></b>
Subcutaneous	no information found
Intramuscular	no information found
Direct intravenous	not recommended since local reaction and thrombophlebitis may result from high local concentrations <sup>6</sup>
<b><i>Intermittent infusion</i></b>	<b><i>over 1 hour<sup>28-30</sup></i></b> , can also be given over 2-4 hours <sup>6,11,12</sup>
Continuous infusion	over 24 hours <sup>4,31</sup>
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found

BC Cancer administration standard noted in ***bold, italics***

Intravesical	no information found
--------------	----------------------

**DOSAGE GUIDELINES:**

Refer to protocol by which patient is being treated.

**Adults:**BC Cancer usual dose noted in ***bold, italics***

	Cycle Length:	
<i>Intravenous:</i>	<b>3-6 weeks<sup>6,11,12,32</sup>:</b>	<b><i>90 mg IV for one dose on day 1</i></b> (total dose per cycle 90 mg)
	<b>4-6 weeks<sup>33,34</sup>:</b>	<b><i>30 mg IV for one dose on day 1</i></b> (total dose per cycle 30 mg)
	<b>6 months<sup>35,36</sup>:</b>	<b><i>90 mg IV for one dose on day 1</i></b> (total dose per cycle 90 mg)
	12 weeks <sup>37</sup> :	90 mg IV for one dose on day 1 (total dose per cycle 90 mg)
<i>for bone loss</i>	12 weeks <sup>10</sup> :	<b><i>60 mg IV for one dose on day 1</i></b>
<i>for hypercalcemia of malignancy</i>	Refer to BC Cancer Protocol Summary Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia (BC Cancer Protocol SCHYPCAL) at <a href="#">Chemotherapy Protocols - Supportive Care</a> .	
<i>Dosage in renal failure:</i>	No adjustment is required when the recommended dose schedule is used. However, a maximum infusion rate of 22.5 mg/h is recommended in patients with renal dysfunction. <sup>6,38</sup> Moreover, there is limited experience with pamidronate in patients with serum creatinine > 440 µmol/L and caution should be used. <sup>6</sup>	
<i>Dosage in hepatic failure:</i>	no adjustment required <sup>6</sup>	
<i>Dosage in dialysis</i>	no information found	
<b><u>Children:</u></b>		
<i>Intravenous:</i>	1-2 mg/kg IV over 3-24 hours has been used for tumour-induced hypercalcemia <sup>39</sup>	

**REFERENCES:**

1. Lipton A. AREDIA® : the once-monthly infusion for the treatment of bone metastases. *Curr Opin Oncol* 1998;10(Suppl 1):S1-5.
2. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. *Drugs* 1991;42(6):919-944.
3. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. *Drugs Aging* 1998;12(2):149-168.
4. USP DI. Volume I. Drug information for the health care professional. Pamidronate. 20th ed. Englewood, Colorado: Micromedex, Inc.; 2000. p. 2368-2370.
5. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. *Br J Haematol* 1998;101(2):280-286.
6. Novartis Pharmaceuticals Canada Inc. AREDIA® product monograph. Laval, Quebec; 30 July 1999.
7. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. *Br J Cancer* 1995;72(5):1289-1293.
8. Watters J, Gerrard G, Dodwell D. The management of malignant hypercalcaemia. *Drugs* 1996;52(6):837-848.
9. Chisholm MA, Mulloy AL, Taylor AT. Acute management of cancer-related hypercalcaemia. *Ann Pharmacother* 1996;30(5):507-513.
10. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2001;345(13):948-955.
11. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma AREDIA® Study Group [see comments]. *J Clin Oncol* 1998;16(2):593-602.
12. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. *J Clin Oncol* 1998;16(6):2038-2044.
13. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 AREDIA® Breast Cancer Study Group. *J Clin Oncol* 1999;17(3):846-854.
14. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. *Cancer* 2000;88(5):1082-1090.
15. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review [see comments]. *J Clin Oncol* 1998;16(3):1218-1225.
16. Marx RE. Pamidronate (ARELIA® ) and zoledronate (ZOMETA® ) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 2003;61(9):1115-1117.
17. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. *Aust Dent J* 2003;48(4):268.
18. Novartis Pharmaceuticals Corporation. Updated safety: possible relationship of AREDIA® (pamidronate sodium) and/or ZOMETA® (zoledronic acid) with osteonecrosis of the jaw. 5 November 2004.
19. Sims EC, Rogers PB, Besser GM, et al. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. *Clin Oncol (Royal College Radiologists)* 1998;10(6):407-409.
20. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 12 August 2016.
21. Hoff AO, Toth BB, Altundag A, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. *J Bone Miner Res* 2008;23:826-836.
22. Berenson JR, Stopeck AT. Medication-related osteonecrosis of the jaw in patients with cancer. In: 2017 UpToDate®; Savarese, Diane MF. (Ed); Waltham, Massachusetts: UpToDate®; Available at [www.uptodate.com](http://www.uptodate.com); updated 3Feb2017; accessed 13Mar2017.
23. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. *J. Oral Maxillofac. Surg* 2014;72(10):1938-1956.
24. Health Canada. MedEffect® summary safety review: assessing the risk of jaw bone loss (osteonecrosis of the jaw). 25 November 2016. Available at: <http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/bisphosphonates-eng.php>. Accessed 4 January 2017.
25. European Medicines Agency. News and Press Releases: Further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine. 27 March 2015. Available at: <http://www.ema.europa.eu/ema/>. Accessed 20 March 2017.
26. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol* 2012;23(5):1341-1347.
27. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015;30(1):3-23.
28. Vilimovskij A, Thuerlimann B, Berenson JR, et al. Renal safety and tolerability of 90mg of aredia (pamidronate) administered as an intravenous 1 hour infusion: preliminary results. *Proc Am Soc Clin Oncol* 1999;18:576a (abstract 2223).
29. Tyrrell CJ, Collinson M, Madsen EL, et al. Intravenous pamidronate: infusion rate and safety. *Ann Oncol* 1994;5(Suppl 7):S27-29.
30. Tyrrell CJ. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. AREDIA® Multinational Cooperative Group. *Ann Oncol* 1994;5(Suppl 7):S37-40.
31. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcaemia. *Clin Nephrol* 1996;45(3):175-179.
32. BC Cancer Agency Breast Tumour Group. (BRAVPAM) BCCA Protocol Summary for Treatment of Acute Bone Pain Secondary to Breast Cancer Metastases Using Pamidronate or IV Clodronate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2016.

33. Gimsing P, Carlson K, Turesson I, Fayers P, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. *Lancet Oncol* 2010 ;11(10):973-982.
34. BC Cancer Agency Multiple Myeloma Tumour Group. (MYPAM) BCCA Protocol Summary for Treatment of Multiple Myeloma With Pamidronate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2016.
35. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials *Lancet* 2015 3–9 October 2015;386(10001):1353-1361.
36. BC Cancer Agency Breast Tumour Group. (UBRAJPAM) BCCA Protocol Summary for Adjuvant Treatment of Post-menopausal Women Using Pamidronate. Vancouver, British Columbia: BC Cancer Agency; 1 December 2017.
37. Amir E, Freedman O, Carlsson L, Dranitsaris G, et al. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. *Am J Clin Oncol* 2013 October;26:436-442.
38. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. *J Clin Pharmacol* 1997;37(4):285-290.
39. Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children [see comments]. *Med Pediatr Oncol* 1998;30(2):117-121.